Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma

BackgroundAdding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metronomic capecitabine in locoregionally advanced NPC.Me...

Full description

Bibliographic Details
Published in:Frontiers in Oncology
Main Authors: Longjiang She, Kun Tian, Jiaqi Han, Weihan Zuo, Zhu Wang, Ning Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Subjects:
cost-effectiveness
metronomic chemotherapy
adjuvant chemotherapy
capecitabine
nasopharyngeal carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.904372/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.904372/full

Similar Items